Mallinckrodt Plc (NYSE:MNK)

127.18
Delayed Data
As of May 22
 -1.63 / -1.27%
Today’s Change
67.18
Today|||52-Week Range
134.26
+28.43%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$14.9B

Company Description

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. The company operates its business through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Specialty Pharmaceuticals segment produces and markets branded pharmaceuticals and biopharmaceuticals, specialty generic pharmaceuticals and active pharmaceutical ingredients consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. The Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems and radiopharmaceuticals. Mallinckrodt was founded on January 9, 2013 and is headquartered in Dublin, Ireland.

Contact Information

Mallinckrodt Plc
Damastown Industrial Estate
Dublin Dublin 15
P:(531) 880-8180
Investor Relations:
3533146546650

Employees

Shareholders

Individual stakeholders7.68%
Other institutional49.67%
Mutual fund holders46.75%

Top Executives

Mark C. TrudeauPresident, Chief Executive Officer & Director
Frank ScholzSenior Vice President-Global Operations
Matthew K. HarbaughChief Financial Officer & Senior Vice President
Mario SaltarelliChief Science Officer & Senior Vice President
Sandra L. HattenSenior VP-Quality & Regulatory Compliance

To view my watchlist

Not a member yet?

Sign up now for a free account